Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Faldaprevir (BI 201335) on QT Interval in Healthy Subjects
NCT02182310Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2008
- Primary completion
- Oct 2008
- Modality
- Small Molecules, Modified Peptides
01
Overview
Phase 1, randomised, double-blind trial of faldaprevir in hepatitis C (HCV) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: QTcI interval (QT interval individually corrected for heart rate) at 8 hours. Started Jun 2008; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02182310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182310.